Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI chefs up: personalized meal plans to outsmart chemo taste changes

NCT ID NCT07040189

Symptom relief Sponsor: Wuerzburg University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 21, 2026 · Last updated Aug 21, 2026

Summary

This trial tests an AI-based platform called Gustabor that creates personalized meal plans for cancer patients experiencing taste disorders from chemotherapy. The study includes adults with multiple myeloma or gastrointestinal cancer who have taste changes and mainly eat by mouth. Participants use the online portal to get recipe suggestions tailored to their specific taste issues. The main goal is to see if patients find the nutritional intervention helpful at their second visit within 12 weeks.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
AI-based web platform (Gustabor) that provides personalized lifestyle tips and recipe recommendations based on the patient's individual data and taste disorder
What this could lead to
If successful, this could offer a practical, personalized way to help cancer patients maintain nutrition and quality of life during treatment.
What could go wrong
This is a small pilot study, so results may not apply broadly. The AI's recommendations may not suit everyone, and the intervention requires internet access and willingness to follow recipes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 51 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2025

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 * Suffering from one of the following tumor entities: Multiple myeloma or malignant tumor of the gastrointestinal tract * Mainly oral nutrition * Subjectively perceived tumor therapy-related taste disorder * At least two clinical presentations planned within 12 weeks with a minimum interval of three weeks * Ability to participate in nutritional intervention, including use of the online portal and implementation of recipe suggestions (e.g. resources and access to a kitchen), either independently or with third-party support (e.g. by relatives, outpatient care services). Exclusion Criteria: * Pregnancy * Taste disorder explained by other causes (e.g. existing before therapy or COVID disease) * Placement in an inpatient care facility

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Gi cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

digestive system cancer digestive system neoplasm plasma cell myeloma Taste Disorders

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Gi cancer Multiple myeloma Taste disorders

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • LMU Klinikum

    COMPLETED

    Munich, Bavaria, 81377, Germany

  • Universitätsklinikum Regensburg

    RECRUITING

    Regensburg, Bavaria, 93053, Germany

  • Universitätsklinikum Würzburg

    RECRUITING

    Würzburg, Bavaria, 97080, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.